Vargas F, Castillo M A, Haro J M
Departamento de Bioquimica, Facultad de Medicina, Universidad de Granada, Spain.
Experientia. 1992 Aug 15;48(8):755-8. doi: 10.1007/BF02124296.
The effects of methimazole, an antithyroid drug, on blood pressure and other parameters were evaluated in the established phase of Goldblatt two-kidney one clip (G2K-1C) hypertension. Methimazole was administered via drinking water for five weeks, starting five weeks after hypertension had been induced. After this period of treatment, similarly high blood pressures were observed in methimazole-treated and non-treated G2K-1 C rats, despite the fact that a hypothyroid state had been achieved in methimazole-treated rats. Methimazole-treated G2K-1 C rats showed reductions in heart rate, ventricular weight, ventricular/body weight ratio and mortality in comparison with rats not treated with methimazole. These results clearly demonstrate that hypothyroidism induced by methimazole: a) does not reverse G2K-1 C hypertension, but b) improves the rate of survival and c) reduces relative cardiac hypertrophy, possibly by the reduction in cardiac work observed in Goldblatt hypothyroid rats.
在戈德布拉特二肾一夹（G2K-1C）高血压模型的建立阶段，评估了抗甲状腺药物甲巯咪唑对血压及其他参数的影响。在高血压诱导五周后，通过饮水给予甲巯咪唑，持续五周。经过这段治疗期后，尽管甲巯咪唑治疗组大鼠已达到甲状腺功能减退状态，但在甲巯咪唑治疗组和未治疗的G2K-1C大鼠中观察到了相似的高血压水平。与未用甲巯咪唑治疗的大鼠相比，甲巯咪唑治疗的G2K-1C大鼠心率、心室重量、心室/体重比及死亡率均有所降低。这些结果清楚地表明，甲巯咪唑诱导的甲状腺功能减退：a）不会逆转G2K-1C高血压，但b）可提高生存率，c）可能通过戈德布拉特甲状腺功能减退大鼠心脏做功的降低而减轻相对心脏肥大。
